Benzinga | Dec 10, 2020 06:20AM EST

Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $170

Needham maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $105 to $170.